Results 41 to 50 of about 46,119 (273)
BMC Cancer, 2019 Background High-risk neuroblastoma with N-Myc amplification remains a therapeutic challenge in paediatric oncology. Antagonism of pro-death Bcl-2 homology (BH) proteins to pro-survival BH members such as Mcl-1 and Bcl-2 has become a treatment approach ...
Stefanie Klenke +5 more
doaj +1 more source
The Clinical Pharmacogenetics Implementation Consortium: 10 Years Later
Clinical pharmacology and therapy, 2019 In 2009, the Clinical Pharmacogenetics Implementation Consortium (CPIC, www.cpicpgx.org), a shared project between Pharmacogenomics Knowledge Base (PharmGKB, http://www.pharmgkb.org) and the National Institutes of Health (NIH), was created to provide ...
M. Relling +5 more
semanticscholar +1 more source
Pharmacogenetics of asthma [PDF]
European Respiratory Journal, 2000 Pharmacogenetics offers the potential to optimize treatment for individual patients by using genetic information to improve efficacy or avoid side effects. While there are a number of examples in which the approach is already in routine clinical usage, exploitation of this approach in asthma is still under development.
openaire +3 more sources
Systematic identification of non-coding pharmacogenomic landscape in cancer
Nature Communications, 2018 In this study the authors build lncRNA-drug response models for 265 anti-cancer agents across 27 cancer types. They report their cancer cell line based lncRNA EN-models are able to effectively predict therapeutic outcome for breast cancer, ovarian cancer,
Yue Wang +6 more
doaj +1 more source
Integrating rare genetic variants into pharmacogenetic drug response predictions
Human Genomics, 2018 Background Variability in genes implicated in drug pharmacokinetics or drug response can modulate treatment efficacy or predispose to adverse drug reactions.
Magnus Ingelman-Sundberg +3 more
doaj +1 more source
The Oncologist, EarlyView., 2021 Abstract Lessons Learned Osimertinib has confirmed effectiveness in this real‐world population of patients with EGFR‐mutant advanced non‐small cell lung cancer. Thromboembolic events occur more frequently than previously reported, suggesting a thrombotic diathesis that requires further investigation. Patients with at least three metastatic sites, brain
Martina Lorenzi +21 more
wiley +1 more source
The pharmacogenetics of methotrexate [PDF]
Rheumatology, 2007 Methotrexate (MTX) is a cornerstone of therapy for rheumatoid arthritis. However, it is not universally effective and up to one-third of patients fail to respond to treatment, either because of inefficacy or adverse events, although at present it is not possible to predict therapy response accurately.
S L, Hider, I N, Bruce, W, Thomson
openaire +2 more sources
miRNAs as Key Players in the Management of Cutaneous Melanoma
Cells, 2020 The number of treatment options for melanoma patients has grown in the past few years, leading to considerable improvements in both overall and progression-free survival.
Celeste Lorusso +4 more
doaj +1 more source
European Journal of Human Genetics, 2019 Despite advances in the field of pharmacogenetics (PGx), clinical acceptance has remained limited. The Dutch Pharmacogenetics Working Group (DPWG) aims to facilitate PGx implementation by developing evidence-based pharmacogenetics guidelines to optimize ...
C. Lunenburg +14 more
semanticscholar +1 more source
Journal of Clinical Medicine, 2021 The implementation of clinical pharmacogenetics in daily practice is limited for various reasons. Today, however, it is a discipline in full expansion.
P. Zubiaur +7 more
semanticscholar +1 more source